Instil Bio, Inc.
In the quarter to June 2026, EPS grew 80.6%, free cash flow grew 68.6% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow TIL
Instil Bio, Inc. (TIL) EV/Sales
As of 16 October 2026, Instil Bio, Inc. (TIL) trades at a EV/Sales of 401×. Over the past ten years it has ranged from −1,290× (December 2022) to 17,612× (September 2021); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 1,314× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2020 | 1,314× | 0.00% |
| Sep 2020 | 1,314× | 0.00% |
| Jun 2020 | 1,314× | 0.00% |
| Mar 2020 | 1,314× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ANVS Annovis Bio, Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| VERU Veru Inc. compare | 1.2× |
| SGMOQ Sangamo Therapeutics, Inc. compare | 1.2× |
| CELU Celularity, Inc. compare | 4.1× |
| SER Serina Therapeutics, Inc. compare | 66.0× |
| GRCE Grace Therapeutics, Inc. compare | 109× |
| TIL Instil Bio, Inc. | 401× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)